Aktie A3DWEE PULMATRIX, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Pulmatrix, Inc.

Aktien

A3DWEE

US74584P3010

PULM

Markt geschlossen - Nasdaq
Andere Börsenplätze
 19:30:00 03.07.2024 		% 5 Tage % 1. Jan.
2,19 USD +9,50 % Intraday Chart für Pulmatrix, Inc. +12,31 % +17,74 %
29.05. MannKind vereinbart Cross-License-Deal mit Pulmatrix MT
17.05. Pulmatrix meldet bis zu $95 Millionen für gemischtes Angebot an MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!
100% kostenlose Registrierung
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
MannKind Agrees to Cross License Deal With Pulmatrix
Pulmatrix Files Up to $95 Million Mixed Shelf
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled Dhe for Acute Migraine
Pulmatrix : Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) - Form 8-K
Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Earnings Flash (PULM) PULMATRIX Reports Q1 Revenue $5.9M
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix Explores Strategic Alternatives
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A3DWEE Aktie
  4. Nachrichten Pulmatrix, Inc.
  5. Andere Sprachen